Ag85A
Greater than 95% as determined by SDS-PAGE.
Description
Recombinant Mycobacterium tuberculosis Ag85A (43-338 a.a) produced in Hi-5 cells is a single, glycosylated polypeptide chain having a molecular mass of 32.8kDa (305 a.a in total).
Antigen 85A is fused to a 6 amino acid His tag at C-terminus and purified by conventional chromatographic techniques.
Product Specs
Product Science Overview
Mycobacterium tuberculosis (M. tuberculosis) is the causative agent of tuberculosis (TB), a disease that remains a significant global health challenge. One of the major secretory proteins of M. tuberculosis is Antigen 85A (Ag85A), which is part of the antigen 85 complex. This complex consists of three proteins: Ag85A, Ag85B, and Ag85C, all of which play crucial roles in the pathogenesis and immune response to TB .
Ag85A is a 30-32 kDa protein that possesses enzymatic mycolyl-transferase activity. This enzyme is involved in the synthesis of the mycobacterial cell wall by catalyzing the transfer of mycolic acids to the arabinogalactan layer, which is essential for the formation of the cell wall and the biogenesis of cord factor . The antigen 85 complex proteins are also known for their ability to bind to extracellular matrix proteins such as fibronectin and elastin .
Ag85A is highly immunogenic and has been shown to induce strong T-cell responses, particularly Th1-type immune responses, which are crucial for controlling intracellular infections like TB . This makes Ag85A a promising candidate for TB vaccine development. In fact, Ag85A has been included in several experimental TB vaccines and has shown potential in enhancing the efficacy of the Bacillus Calmette-Guérin (BCG) vaccine .
Recombinant Ag85A refers to the protein produced through recombinant DNA technology, which involves inserting the gene encoding Ag85A into a suitable expression system, such as Escherichia coli or mammalian cells. This allows for the large-scale production of Ag85A for research, diagnostic, and vaccine development purposes .
- Vaccine Development: Recombinant Ag85A is being explored as a component of new TB vaccines. It has been shown to boost the immune response when used in combination with other antigens or adjuvants .
- Diagnostic Tools: Due to its immunogenicity, recombinant Ag85A is used in various diagnostic assays to detect TB infection. These assays include enzyme-linked immunosorbent assays (ELISA), lateral flow immunoassays, and immunoblots .
- Research: Recombinant Ag85A is used in research to study the immune response to TB and to develop new therapeutic strategies .
